 | Up a level |
2018
Waldschmidt, D., Merle, P., Granito, A., Huang, Y-H, Bodoky, G., Yokosuka, O., Rosmorduc, O., Breder, V. V., Gerolami, R., Masi, G., Ross, P. J., Qin, S., Song, T., Bronowicki, J-P, Ollivier-Hourmand, I, Kudo, M., Xu, L., Baumhauer, A., Meinhardt, G., Han, G. and Bruix, J. (2018). Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib. Oncol. Res. Treat., 41. S. 281 - 282. BASEL: KARGER. ISSN 2296-5262
2014
Giannelli, G., Faivre, S., Santoro, A., Kelley, R. K., Merle, P., Gane, E., Douillard, J. -Y., Waldschmidt, D., Mulcahy, M., Costentin, C., Minguez, B., Papappicco, P. P., Gueorguieva, I., Cleverly, A., Desaiah, D., Lahn, M. M., Ameryckx, S., Benhadji, K. A. and Raymond, E. (2014). EVALUATION OF LY2157299 MONOHYDRATE (LY), A TGF-beta RECEPTOR I KINASE INHIBITOR, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: PHASE 2 STUDY RESULTS OF SAFETY, EFFICACY AND PK/PD. J. Hepatol., 60 (1). S. S52 - 2. AMSTERDAM: ELSEVIER SCIENCE BV. ISSN 1600-0641